HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 9, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at

FDA deferred action on the BLA for ROLONTIS ® (eflapegrastim)   due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 insertion mutations in previously treated

HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 28, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate

Agency cites inability to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel restrictions HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 26, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 14, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 8, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at

Recently announced positive topline results in HER2 exon 20 insertion mutations from Cohort 2 of the poziotinib ZENITH20 trial Company is in process of requesting a pre-NDA meeting with the FDA seeking an indication for second-line NSCLC patients with HER2 exon 20 insertion mutations BLA for

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 5, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the underwriters of its previously announced public offering of common

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 3, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate

HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 30, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the pricing of an underwritten public offering of 21,666,667 shares of its

HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 29, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq-GS: SPPI) (“Spectrum”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered

Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 27, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it met the

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 22, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced preclinical data evaluating the administration of ROLONTIS ® (eflapegrastim) on the same day as

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 16, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 3, 2020-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling , M.D., MBA, has been named Senior Vice President, Clinical Development.

HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at

BLA for ROLONTIS ® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to host webcast and conference call

HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as